Regulatory Bayer’s asundexian starts EU review for ischaemic stroke PharmaphorumThe EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J J.CardiovascularRead full story pharminent June 10, 2026 (Last updated: June 10, 2026) Pharmaphorum The EMA has started its review of Bayer’s asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J J. Cardiovascular Read full story Post navigation Previous: AbbVie’s migraine drug cleared for migraine attacks on NHSNext: Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026